Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Amisulpride→

Amisulpride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
71675-85-9
Molecular formula
C17H27N3O4S
Molecular weight
369.5 g/mol
Drug class
Atypical antipsychoticselective dopamine D2/D3 receptor antagonist
Mechanism of action
Selectively antagonises dopamine D2 and D3 receptors in limbic and other dopaminergic pathways. At therapeutic doses it reduces dopaminergic neurotransmission associated with psychotic symptoms; effects depend on dose and receptor occupancy.
Indications / reported uses
  • Treatment of schizophrenia, including positive and negative symptoms, under product-specific authorisation; oral and intravenous formulations may have different indications in different jurisdictions

Sources: UK SmPC — Amisulpride tablets · NLM MeSH — Amisulpride · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Amisulpride Environmental Risk Assessment (ERA) (the Amisulpride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.